Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma | MicrobiomeTrials← Back to trialsNCT07628595
Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
RecruitingEARLY_PHASE1INTERVENTIONAL
Trial Details
Start: 2026-07-01Est. Completion: 2027-12-31
Enrollment target: 19 participants Locations- The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Other microbiome trials you might be interested in
Multiple Myeloma (MM)Multiple Myeloma RefractoryMultiple Myeloma in RelapseMultiple Myeloma
This is a Phase II, open-label, nonrandomized, single-arm study of elranatamab that will be administered in the outpatie…
Multiple LocationsEst. completion Oct 2029
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
Background:
Multiple myeloma (MM) is a type of blood cancer that affects a person s immunity. MM returns after treatmen…
Bethesda, United States
Completed Jan 1, 2033